Abstract 13142: The Atrial Fibrillation Effect on Quality-of-Life Study: A New, Validated, and Comprehensive Quality-of-Life Tool for Atrial Fibrillation (AF)
Introduction: In contrast to generic health related quality-of-life (HRQoL) instruments, disease-specific questionnaires allow patients to quantify their illness burden and the extent to which this is attributable to a specific disease. We developed a comprehensive instrument to measure the effect of treatment on the HRQoL in patients with AF and compared it to generic questionnaires.
Methods: The 20-item AFEQT questionnaire was developed for use as a self-administered outcome measure. Four conceptual domains (Symptoms, Daily Activities, Treatment Concern, and Treatment Satisfaction) were established. Domain and global scores were calculated. Participants from six centers completed the AFEQT, SF-36 and EQ-5D at baseline (pre-intervention) and at 3 and 12 months. Changes at 3 and 12 months following intervention of a change in antiarrhythmic drug therapy or AF ablation were used to assess responsiveness.
Results: Among 211 of 219 patients (age 62 ±11.9 years) with evaluable data, AFEQT completion rates were 94% at baseline and Month 3 and 66% at Month 12. AF was paroxysmal in 66%, persistent in 24%, longstanding persistent in 5%, and permanent in 5%. Change in AFEQT scores was larger after ablation than with pharmacological adjustments. AFEQT global and domain scores were also more responsive to clinical change than the SF-36 and EQ-5D (Table 1).
Conclusion: The AFEQT is a newly validated, comprehensive, and disease-specific instrument for AF that is sensitive to different types of treatment and more responsive to treatment related changes than the generic QoL questionnaires.
- © 2010 by American Heart Association, Inc.